180 related articles for article (PubMed ID: 34747507)
1. Clinical response to rituximab and improvement in quality of life in patients with bullous pemphigoid and mucous membrane pemphigoid.
Rashid H; Meijer JM; Bolling MC; Horváth B
Br J Dermatol; 2022 Apr; 186(4):721-723. PubMed ID: 34747507
[No Abstract] [Full Text] [Related]
2. Anti-laminin 332 mucous membrane pemphigoid in a young woman treated with rituximab.
Gitin A; Porta AD; Bisbee E; Braunlich K; Motaparthi K
Dermatol Online J; 2022 Aug; 28(4):. PubMed ID: 36259856
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases.
Lamberts A; Euverman HI; Terra JB; Jonkman MF; Horváth B
Front Immunol; 2018; 9():248. PubMed ID: 29520266
[TBL] [Abstract][Full Text] [Related]
4. Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients.
Lourari S; Herve C; Doffoel-Hantz V; Meyer N; Bulai-Livideanu C; Viraben R; Maza A; Adoue D; Bedane C; Paul C
J Eur Acad Dermatol Venereol; 2011 Oct; 25(10):1238-40. PubMed ID: 21054575
[No Abstract] [Full Text] [Related]
5. Clinical outcome and safety of rituximab therapy for pemphigoid diseases.
Tovanabutra N; Payne AS
J Am Acad Dermatol; 2020 May; 82(5):1237-1239. PubMed ID: 31738960
[No Abstract] [Full Text] [Related]
6. The top 10 research priorities for the treatment of bullous pemphigoid, mucous membrane pemphigoid and pemphigus vulgaris in the UK: results of a James Lind Alliance Priority Setting Partnership.
Harman KE; Barha J; Chalmers JR; Dart JKG; Davies I; Ellis P; Grindlay D; Hampton PJ; Hill S; Hockey S; Lloyd-Lavery A; McPhee M; Murphy R; Rauz S; Setterfield JF; Thompson I; Westmoreland M; Waistell C
Br J Dermatol; 2023 Sep; 189(4):469-498. PubMed ID: 37201904
[No Abstract] [Full Text] [Related]
7. Consensus on the treatment of autoimmune bullous dermatoses: bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita - Brazilian Society of Dermatology.
Santi CG; Gripp AC; Roselino AM; Mello DS; Gordilho JO; Marsillac PF; Porro AM
An Bras Dermatol; 2019 Apr; 94(2 Suppl 1):33-47. PubMed ID: 31166405
[TBL] [Abstract][Full Text] [Related]
8. Remission of Anti-laminin 332 Mucous Membrane Pemphigoid Associated with Non-small Cell Lung Cancer after Therapy with Rituximab and Intravenous Immunoglobulin.
Tarnowietzki E; Peters T; Kraus L; Schmidt E; Scharffetter-Kochanek K
Acta Derm Venereol; 2020 Oct; 100(17):adv00301. PubMed ID: 32852563
[No Abstract] [Full Text] [Related]
9. Rituximab Therapy for Mucous Membrane Pemphigoid: A Retrospective Monocentric Study With Long-Term Follow-Up in 109 Patients.
Bohelay G; Alexandre M; Le Roux-Villet C; Sitbon I; Doan S; Soued I; Shourick J; Rousset L; Mellottee B; Heller M; Lièvre N; Zumelzu C; Morin F; Grootenboer-Mignot S; Gabison E; Caux F; Prost-Squarcioni C; Musette P
Front Immunol; 2022; 13():915205. PubMed ID: 35844526
[TBL] [Abstract][Full Text] [Related]
10. A Retrospective Study of Patient-Reported Data of Bullous Pemphigoid and Mucous Membrane Pemphigoid From a US-Based Registry.
Lee J; Seiffert-Sinha K; Attwood K; Sinha AA
Front Immunol; 2019; 10():2219. PubMed ID: 31608053
[TBL] [Abstract][Full Text] [Related]
11. Retrospective analysis of the long-term therapeutic effectiveness and safety profile of rituximab in the treatment of mucous membrane pemphigoid in a German university center between 2008 and 2019.
Bamberger F; König IR; Gola D; Zillikens D; Sadik CD
Front Immunol; 2023; 14():1180150. PubMed ID: 37143653
[TBL] [Abstract][Full Text] [Related]
12. A case of mucous membrane pemphigoid with anti-BP230 autoantibodies alone.
Yoshimoto N; Ujiie I; Inamura E; Natsuga K; Nishie W; Shimizu H; Ujiie H
Int J Dermatol; 2021 Mar; 60(3):e92-e94. PubMed ID: 32970829
[No Abstract] [Full Text] [Related]
13. Localized genital mucous membrane pemphigoid of the penis: Notes on two cases.
Joly E; Seta V; Plantier F; Dupin N; Chanal J
Ann Dermatol Venereol; 2021 Sep; 148(3):202-203. PubMed ID: 34183172
[No Abstract] [Full Text] [Related]
14. Rituximab in autoimmune pemphigoid diseases: Indications, optimized regimens, and practice gaps.
Thomas RM; Colon A; Motaparthi K
Clin Dermatol; 2020; 38(3):384-396. PubMed ID: 32563354
[TBL] [Abstract][Full Text] [Related]
15. Bronchial involvement in mucous membrane pemphigoid: 2 cases and a literature review.
Rousset L; Bohelay G; Gille T; Le Roux-Villet C; Kambouchner M; Levy A; Brauner M; Tandjaoui H; Aucouturier F; Mignot S; Caux F; Prost-Squarcioni C; Alexandre M
Ann Dermatol Venereol; 2023 Mar; 150(1):64-70. PubMed ID: 36435654
[No Abstract] [Full Text] [Related]
16. Targeting interleukin 4 receptor α: A new approach to the treatment of cutaneous autoimmune bullous diseases?
Russo R; Cozzani E; Gasparini G; Parodi A
Dermatol Ther; 2020 Jan; 33(1):e13190. PubMed ID: 31863534
[TBL] [Abstract][Full Text] [Related]
17. Methotrexate for oral mucous membrane (cicatricial) pemphigoid: experience at an academic dermatology outpatient clinic.
Hrin ML; Williams JA; Bowers NL; Ahn CS; Strowd LC
J Am Acad Dermatol; 2022 Dec; 87(6):1431-1433. PubMed ID: 35948167
[No Abstract] [Full Text] [Related]
18. Use of rituximab in the treatment of mucous membrane pemphigoid: An analytic review.
Farooq MM; Miloslavsky EM; Konikov N; Ahmed AR
Autoimmun Rev; 2022 Aug; 21(8):103119. PubMed ID: 35688385
[TBL] [Abstract][Full Text] [Related]
19. Childhood Vulvar Mucous Membrane Pemphigoid
Marti-Marti I; Rizo-Potau D; Gómez S; Pallarès H; Iranzo P
J Pediatr Adolesc Gynecol; 2022 Apr; 35(2):171-173. PubMed ID: 34740758
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
